CA-CYOLO
8.5.2024 14:31:36 CEST | Business Wire | Press release
Cyolo, the secure remote access company for operational technology (OT) and industrial control systems (ICS), today announced a strategic partnership with Dragos, a global leader in cybersecurity for ICS/OT. Under the umbrella of Cyolo’s CyoloVerse partner program, Cyolo's PRO Secure Remote Access Platform will work with Dragos’s industry-leading OT cybersecurity platform. This collaboration will provide organizations with a robust and interoperable solution to protect their critical infrastructure against cyber threats.
New technology implementations in ICS/OT environments pose unique risks for critical infrastructure. Today’s risks include lack of support for modern authentication or connectivity methods in traditional environments, connecting existing infrastructure with highly vulnerable end-of-life operating systems, or risk of breaches from third-party remote access.
This interoperability is designed to provide OT customers visibility and management of their asset inventory and enhance asset vulnerability detection and remediation capabilities through a seamless secure controlled access platform.
“Cyolo ICS/OT security and safety expertise are changing the way organizations understand secure remote access,” said Matt Cowell, VP of Business Development at Dragos. “With our companies’ complementary capabilities and unique strengths, we can manage security through the different layers of the operational environment and protect a wider array of organizations across critical infrastructure. Ultimately reducing risk as they expand connectivity.”
Bringing the Cyolo PRO platform alongside the Dragos OT-native network visibility and monitoring offerings gives an unparalleled advantage. The Dragos Platform enables organizations to scale protection, the threat intelligence to keep on top of current threats, and the tools to respond quickly to incidents. With Cyolo’s robust role-based access, application, and policy control, in the future the Dragos Platform will be able to manage Cyolo’s Identity-based parameters (users, applications, resources, policy) in accordance with SOC / IR policies and guidelines.
Together Cyolo and Dragos deliver a comprehensive ICS/OT security framework based on the five critical controls of effective ICS/OT security:
- ICS incident response—which integrates operational insights into incident handling, enhancing system integrity and recovery (Dragos)
- Defensible architecture—ensuring robust visibility, segmentation, and enforcement mechanisms to bridge technological and human aspects of security (Dragos and Cyolo PRO)
- ICS network visibility monitoring—employing continuous monitoring and protocol-aware tools to detect and address potential vulnerabilities (Dragos)
- Remote Access Security—ensuring safe and secure stringent access control in the face of evolving hybrid work environments (Cyolo PRO)
- Risk-based vulnerability management—prioritizing and addressing vulnerabilities based on their potential to pose significant operational risks, thereby ensuring proactive prevention, response, and recovery actions (Dragos and Cyolo PRO)
The solution plans to integrate Cyolo PRO and the Dragos Platform through an API architecture or operator console. It will deliver unsurpassed visibility and control of critical digital assets through secure identity-based access. Together, both companies will deliver simpler, stronger, and more efficient security controls that lay the foundation for Zero Trust (NIST 800-207).
“With this industry leading partnership, Cyolo joins Dragos to address security and operational challenges impacting OT environments," said Joe O’Donnell, EVP Corporate Development and OT GM at Cyolo. “The interoperability of the Dragos Platform and Cyolo PRO provides OT practitioners and industrial organizations with the full spectrum of cybersecurity services across the 5 ICS/OT Critical Controls. The timing could not be better as the world aggressively embraces Industry 4.0.”
Dino Busalachi, CTO and Co-Founder at Velta Technology - a joint partner - also highlighted that “In light of the surge in cyber threats, the growing adoption of Industry 4.0, and the inherent risks within OT environments, Velta Technology understands the critical need to partner with Cyolo and Dragos. Their joint solutions will provide our customers in the industrial sector with a tailored approach that strengthens their access security and elevates their overall security posture.”
Dragos and Cyolo respond to the need for secure industrial networks without disrupting operations, compromising safety or risking non-compliance.
The Dragos Platform offers the most effective industrial cybersecurity technology, giving customers visibility into their ICS/OT assets, vulnerabilities, threats, and response actions. The strength behind the Dragos Platform comes from Dragos’s ability to codify industry-leading OT threat intelligence, and insights from the Dragos services team into the software.
About Cyolo
Cyolo helps IT and ICS organizations stay secure and productive in an era of distributed workforces and unprecedented cyber threats. Cyolo’s platform enables all users, including employees, third parties, and remote or on-site workers, to connect to their working environments seamlessly and securely via modern identity-based authentication. With one unified solution that integrates with your existing tech stack, Cyolo makes securely connecting people to their work simple. To learn more, visit https://cyolo.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508290964/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
